Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
SMARTSCORE: 3.4/5
Asymchem Laboratories Tianjin (002821 CH)
Watchlist
79
Analysis
Health Care
•
China
Asymchem Laboratories (Tianjin) Co., Ltd. operates as a pharmaceutical company. The Company researches, produces, and sells organic and inorganic chemicals, medicines, and other related products. Asymchem Laboratories serves customers worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Innovent Biologics Inc
•
06 Mar 2024 00:55
2024 High Conviction Update: Innovent (1801.HK) - Recent Promising Business Updates and 2024 Outlook
Innovent's product revenue growth will remain strong in 2024.The main flashpoint for performance is after the approval of mazdutide in...
Xinyao (Criss) Wang
Follow
442 Views
Share
bullish
•
Midea Group Co Ltd A
•
25 Oct 2023 00:31
Midea A/H Listing - Early Look - Probably Raising Acquisition Currency
Midea officially filed for an H-share listing yesterday. As per media reports the company is looking to raise up to US$3bn in Hong Kong.
Sumeet Singh
Follow
978 Views
Share
bullish
•
Thematic (Sector/Industry)
•
09 Oct 2023 00:55
China's Weight Loss Drug Market – The Investment Opportunities and the Risks Behind
The GLP-1 target has been recognized as a blockbuster target, which has attracted great enthusiasm from investors.We analyzed related investment...
Xinyao (Criss) Wang
Follow
446 Views
Share
bearish
•
Quantitative Analysis
•
16 Mar 2025 02:00
A-H Premium Weekly (Mar 14th): CIMC, Sinotrans, Joinn Lab, Huahong Semicon, Huaneng Power
We analyzed A-H premium changes in the past week and highlight A-H premium changes for CIMC, Sinotrans, Joinn Lab, Huahong Semicon, Huaneng Power,...
Ke Yan, CFA, FRM
Follow
320 Views
Share
bullish
•
Jiangsu Hengrui Medicine
•
12 Feb 2025 02:44
Jiangsu Hengrui Pharma A/H Listing - Innovation and Overseas Expansion Driving Earnings Rebound
Jiangsu Hengrui Medicine (600276 CH) a China-based pharmaceutical company, aims to raise around US$2bn in its H-share listing.
Sumeet Singh
Follow
387 Views
Share
1
2
3
4
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.51.2
x